STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Guardant Health director and Chief Legal Officer John G. Saia reported transactions on Form 4 showing equity activity dated 09/15/2025. The filing discloses that 1,019 restricted stock units vested and were converted into 1,019 shares, of which the company retained a portion to satisfy tax withholding (the filing states the retained amount equaled the tax liability). Also on 09/15/2025 Mr. Saia sold 535 shares at $54.79 per share. After these transactions he beneficially owned 45,967 shares of Guardant Health common stock.

Positive

  • RSU vesting resulted in an increase of 1,019 shares to the reporting person's holdings, reflecting compensation realization
  • Company retained only the necessary shares for tax withholding, as stated, indicating standard post-vesting treatment

Negative

  • Disposition of 535 shares at $54.79 represents insider selling activity which some investors may view as liquidity-taking
  • Net change reduces immediately liquid holdings compared with the gross vesting amount due to the sale and withholding

Insights

TL;DR: Officer exercised vesting-driven share receipt while selling a smaller block, a routine insider liquidity event.

The Form 4 shows a vesting of 1,019 restricted stock units and a contemporaneous sale of 535 shares at $54.79. The company retained shares to cover tax withholding, which is standard for RSU vesting. This pattern—vesting-driven shares coupled with a partial sale—typically reflects routine compensation settlement and personal liquidity rather than signaling corporate governance change. The filing lists 45,967 shares beneficially owned after activity, a meaningful but not controlling stake.

TL;DR: Insider net increase in holdings from RSU vesting offset by a small sale; impact on float and valuation is likely immaterial.

The reported transactions include an M-code acquisition of 1,019 shares from RSU vesting and an F-code disposition of 535 shares at $54.79. The retained shares for tax withholding are explicitly noted as not exceeding the tax liability. Given the reported post-transaction beneficial ownership of 45,967 shares, the transactions are modest relative to typical public-company floats and are unlikely to materially affect the company’s share supply or signal major insider sentiment shifts.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Saia John G.

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/15/2025 M 1,019 A $0 45,967 D
Common Stock 09/15/2025 F 535(1) D $54.79 45,432 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 09/15/2025 M 1,019 (2) (3) Common Stock 1,019 $0 3,059 D
Explanation of Responses:
1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
2. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024. The remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
3. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia 09/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did John G. Saia report on Guardant Health (GH) Form 4?

The Form 4 reports vesting of 1,019 restricted stock units converted to 1,019 shares and a sale of 535 shares at $54.79, both dated 09/15/2025.

How many Guardant Health shares does John G. Saia beneficially own after the reported transactions?

The filing states Mr. Saia beneficially owned 45,967 shares of Guardant Health common stock following the transactions.

Why did the company retain some shares upon vesting?

The company retained shares to satisfy tax withholding obligations; the filing notes the retained amount was not in excess of the tax liability.

When did these insider transactions occur?

All reported transactions on the Form 4 are dated 09/15/2025, and the form is signed on 09/17/2025.

Was the sale of shares large relative to the vested amount?

Yes, 535 shares were sold, which is about half of the 1,019 shares that vested on that date.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

14.45B
123.40M
4.5%
99.11%
6.43%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO